BioSpace News Archive

Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, today announced that it has closed the previously announced registered direct offering pursuant to which the company entered into a definitive securities purchase agreement

LifeNet Health, the global leader in regenerative medicine biologics, is creating new possibilities in patient care with MatrionTM, a breakthrough decellularized placental membrane for wound healing.

SHINE Medical Technologies LLC announced that its Therapeutics division has made its first commercial sales of lutetium-177 to multiple customers.

The Feinstein Institutes for Medical Research has been awarded a multi-year subcontract from The Frederick National Laboratory for Cancer Research (FNL), currently operated by Leidos Biomedical Research, Inc. for the National Cancer Institute (NCI), to establish a Capacity Building Center (CBC) to further develop and deploy serological (antibody) testing assays for the novel coronavirus disease 2019 (COVID-19).

CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data in seven patients from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9 gene-editing therapy CTX001 in severe hemoglobinopathies has been accepted for an oral presentation during the Plenary Scientific Session at the annual ASH Meeting and Exposition, which will take place virtually from December 5-8, 2020

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has signed a Framework Agreement with the China CDC, Beijing Guoxin Haixiang Equity Investment Partnership, and Beijing Youfeng International Consulting Co., Ltd for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China.

VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today announced the appointments of Sarah Holland, Ph.D., as Chief Business Officer and Aditya Venugopal, Ph.D., as Vice President of Business Development.

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced the release of two abstracts at the American Society of Hematology (ASH) Annual Meeting, one oral presentation of initial data for its BALLI-01 clinical trial and one Trials in Progress poster presentation of its AMELI-01 clinical trial.

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (“NHL”), have been s

New Procedure Kits and Hybrid Tubing Streamline Procedures and Facilitate Post-Procedure Pre-Cleaning